The Stem Study

We are evaluating the safety, tolerability, and effectiveness of the study medication in healthy individuals.

Myeloproliferative Neoplasms (MPNs) are diseases where the bone marrow produces too many red blood cells, white blood cells, or platelets. These conditions are often driven by a specific mutation called JAK2V617F. This study drug is being developed as a potential new treatment that targets this mutation, providing a more focused approach with fewer side effects compared to current treatments.

This initial phase is crucial before testing the study medication in patients with MPNs. By participating, you will contribute to research that could enhance future treatments and positively impact individuals and families affected by these diseases.

Call us on 1300 169 953 to discuss your eligibility today!